<p>Sheets Smith Investment Management 在最近向證券交易委員會（SEC）提交的 13F 表格中表示，在第三季度收購了 Journey Medical Corporation（納斯達克代碼：DERM - 免費報告）的新股份。該基金收購了 132,904 股公司股票，價值約 946,000 美元。Sheets Smith Investment Management 在最近的報告期末持有 Journey Medical 約 0.51% 的股份。</p>
<p>獲取 <strong>Journey Medical</strong> 警報：</p>
<p>其他幾家機構投資者和對沖基金最近也對該公司的持倉進行了調整。Titleist Asset Management LLC 在第一季度將其在 Journey Medical 的持股增加了 18.3%。Titleist Asset Management LLC 目前持有 12,900 股公司股票，價值 76,000 美元，此前在該期間內又收購了 2,000 股。新澤西州警察和消防員退休系統在第二季度購買了 Journey Medical 的新股份，價值約 29,000 美元。美國銀行（Bank of America Corp DE）在第二季度將其在 Journey Medical 的持股增加了 4,707.0%。美國銀行（Bank of America Corp DE）目前持有 4,134 股公司股票，價值 30,000 美元，此前在該期間內又購買了 4,048 股。Raymond James Financial Inc. 在第二季度購買了 Journey Medical 的新股份，價值 36,000 美元。最後，Pale Fire Capital SE 在第二季度將其在 Journey Medical 的持倉增加了 19.0%。Pale Fire Capital SE 目前持有 32,458 股公司股票，價值 233,000 美元，此前在該期間內又購買了 5,184 股。機構投資者持有公司 7.25% 的股份。</p>
<h2>Journey Medical 股票上漲 2.1%</h2>
<p>DERM 股票週五開盤價為 7.92 美元。該公司的市值為 2.1495 億美元，市盈率為 -22.63，貝塔值為 0.80。公司的 50 日移動平均價格為 7.90 美元，200 日移動平均價格為 7.44 美元。Journey Medical Corporation 的 52 周低點為 3.54 美元，52 周高點為 9.40 美元。該公司的債務與股本比率為 0.75，速動比率為 1.12，流動比率為 1.42。</p>
<p>Journey Medical（納斯達克代碼：DERM - 獲取免費報告）最近在 11 月 12 日（星期三）公佈了季度財報。該公司報告季度每股收益（EPS）為（0.09）美元，低於分析師一致預期的（0.08）美元，差額為（0.01）美元。該季度的營業收入為 1763 萬美元，而分析師預期為 1885 萬美元。Journey Medical 的淨利潤率為 -14.58%，股本回報率為 -39.94%。平均而言，股票研究分析師預計 Journey Medical Corporation 本財年將發佈 -1.02 的每股收益。</p>
<h2>華爾街分析師預測增長</h2>
<p>多家券商最近對 DERM 進行了評估。HC Wainwright 在 8 月 25 日的研究報告中開始覆蓋 Journey Medical。他們給予該公司 &#34;買入&#34; 評級，目標價為 13.00 美元。Zacks Research 在 10 月 13 日的報告中將 Journey Medical 的評級從 &#34;強烈賣出&#34; 上調至 &#34;持有&#34;。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Journey Medical 的 &#34;賣出（d-）&#34; 評級。三位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 &#34;持有&#34;，平均目標價為 12.17 美元。</p>
<p><strong>閲讀我們對 DERM 的最新分析</strong></p>
<h2>Journey Medical 公司簡介</h2>
<p>（免費報告）</p>
<p>Journey Medical Corporation 專注於開發和商業化用於治療美國皮膚病的藥品。該公司的市場產品包括 Qbrexza，一種用於治療原發性腋下多汗症的藥用濕巾；Accutane，一種用於治療嚴重頑固性結節性痤瘡的口服異維 A 酸藥物；以及 Amzeeq，一種用於治療中度至重度非結節性痤瘡炎症病變的米諾環素外用製劑。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Journey Medical 更好</li>
<li>大型股定義及如何投資</li>
<li>博通股票暴跌 20%——但華爾街認為其將飆升至 500 美元</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>忘掉芯片：AI 反彈的 4 個工業投資機會</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>MongoDB 可能會創下新高——但你需要迅速行動</li>
</ul>
<p><strong>想看看其他對沖基金持有 DERM 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 Journey Medical Corporation（納斯達克代碼：DERM - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Journey Medical 嗎？</h2>
<p>在你考慮 Journey Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就購買，以便在更廣泛的市場注意到之前……而 Journey Medical 並不在名單上。</p>
<p>雖然 Journey Medical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

DERM

<p>Sheets Smith Investment Management 在第三季度收購了 132,904 股 Journey Medical Corporation，價值約為 946,000 美元。這筆收購代表了該公司約 0.51% 的股份。其他機構投資者也對 Journey Medical 的持倉進行了調整。該公司的股票開盤價為 7.92 美元，市值為 2.1495 億美元。分析師對該股票的評級不一，普遍評級為 “持有”，平均目標價為 12.17 美元</p>

<p>Sheets Smith Investment Management acquired a new position in shares of Journey Medical Corporation (NASDAQ:DERM - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 132,904 shares of the company's stock, valued at approximately $946,000. Sheets Smith Investment Management owned approximately 0.51% of Journey Medical at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Sheets Smith Investment Management 在最近向證券交易委員會（SEC）提交的 13F 表格中表示，在第三季度收購了 Journey Medical Corporation（納斯達克代碼：DERM - 免費報告）的新股份。該基金收購了 132,904 股公司股票，價值約 946,000 美元。Sheets Smith Investment Management 在最近的報告期末持有 Journey Medical 約 0.51% 的股份。</p>
</div><p>Get <strong>Journey Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Journey Medical</strong> 警報：</p>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in the company. Titleist Asset Management LLC lifted its holdings in Journey Medical by 18.3% in the first quarter. Titleist Asset Management LLC now owns 12,900 shares of the company's stock valued at $76,000 after acquiring an additional 2,000 shares during the period. Police &amp; Firemen s Retirement System of New Jersey purchased a new position in shares of Journey Medical during the 2nd quarter worth about $29,000. Bank of America Corp DE raised its holdings in shares of Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock worth $30,000 after buying an additional 4,048 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Journey Medical during the second quarter worth $36,000. Finally, Pale Fire Capital SE boosted its position in Journey Medical by 19.0% in the 2nd quarter. Pale Fire Capital SE now owns 32,458 shares of the company's stock valued at $233,000 after buying an additional 5,184 shares during the period. Institutional investors own 7.25% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也對該公司的持倉進行了調整。Titleist Asset Management LLC 在第一季度將其在 Journey Medical 的持股增加了 18.3%。Titleist Asset Management LLC 目前持有 12,900 股公司股票，價值 76,000 美元，此前在該期間內又收購了 2,000 股。新澤西州警察和消防員退休系統在第二季度購買了 Journey Medical 的新股份，價值約 29,000 美元。美國銀行（Bank of America Corp DE）在第二季度將其在 Journey Medical 的持股增加了 4,707.0%。美國銀行（Bank of America Corp DE）目前持有 4,134 股公司股票，價值 30,000 美元，此前在該期間內又購買了 4,048 股。Raymond James Financial Inc. 在第二季度購買了 Journey Medical 的新股份，價值 36,000 美元。最後，Pale Fire Capital SE 在第二季度將其在 Journey Medical 的持倉增加了 19.0%。Pale Fire Capital SE 目前持有 32,458 股公司股票，價值 233,000 美元，此前在該期間內又購買了 5,184 股。機構投資者持有公司 7.25% 的股份。</p>
</div><h2>Journey Medical Stock Up 2.1%</h2>
<div class="lb-trans"><h2>Journey Medical 股票上漲 2.1%</h2>
</div><p>DERM stock opened at $7.92 on Friday. The firm has a market capitalization of $214.95 million, a price-to-earnings ratio of -22.63 and a beta of 0.80. The company's 50 day moving average price is $7.90 and its 200 day moving average price is $7.44. Journey Medical Corporation has a fifty-two week low of $3.54 and a fifty-two week high of $9.40. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.12 and a current ratio of 1.42.</p>
<div class="lb-trans"><p>DERM 股票週五開盤價為 7.92 美元。該公司的市值為 2.1495 億美元，市盈率為 -22.63，貝塔值為 0.80。公司的 50 日移動平均價格為 7.90 美元，200 日移動平均價格為 7.44 美元。Journey Medical Corporation 的 52 周低點為 3.54 美元，52 周高點為 9.40 美元。該公司的債務與股本比率為 0.75，速動比率為 1.12，流動比率為 1.42。</p>
</div><p>Journey Medical (NASDAQ:DERM - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). The business had revenue of $17.63 million during the quarter, compared to analyst estimates of $18.85 million. Journey Medical had a negative net margin of 14.58% and a negative return on equity of 39.94%. On average, equities research analysts anticipate that Journey Medical Corporation will post -1.02 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Journey Medical（納斯達克代碼：DERM - 獲取免費報告）最近在 11 月 12 日（星期三）公佈了季度財報。該公司報告季度每股收益（EPS）為（0.09）美元，低於分析師一致預期的（0.08）美元，差額為（0.01）美元。該季度的營業收入為 1763 萬美元，而分析師預期為 1885 萬美元。Journey Medical 的淨利潤率為 -14.58%，股本回報率為 -39.94%。平均而言，股票研究分析師預計 Journey Medical Corporation 本財年將發佈 -1.02 的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of brokerages recently weighed in on DERM. HC Wainwright started coverage on Journey Medical in a research note on Monday, August 25th. They set a &#34;buy&#34; rating and a $13.00 price objective for the company. Zacks Research raised shares of Journey Medical from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 13th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Journey Medical in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average price target of $12.17.</p>
<div class="lb-trans"><p>多家券商最近對 DERM 進行了評估。HC Wainwright 在 8 月 25 日的研究報告中開始覆蓋 Journey Medical。他們給予該公司 &#34;買入&#34; 評級，目標價為 13.00 美元。Zacks Research 在 10 月 13 日的報告中將 Journey Medical 的評級從 &#34;強烈賣出&#34; 上調至 &#34;持有&#34;。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Journey Medical 的 &#34;賣出（d-）&#34; 評級。三位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 &#34;持有&#34;，平均目標價為 12.17 美元。</p>
</div><p><strong>Read Our Latest Analysis on DERM</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 DERM 的最新分析</strong></p>
</div><h2>Journey Medical Profile</h2>
<div class="lb-trans"><h2>Journey Medical 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.</p>
<div class="lb-trans"><p>Journey Medical Corporation 專注於開發和商業化用於治療美國皮膚病的藥品。該公司的市場產品包括 Qbrexza，一種用於治療原發性腋下多汗症的藥用濕巾；Accutane，一種用於治療嚴重頑固性結節性痤瘡的口服異維 A 酸藥物；以及 Amzeeq，一種用於治療中度至重度非結節性痤瘡炎症病變的米諾環素外用製劑。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Journey Medical</li>
<li>Large Cap Stock Definition and How to Invest</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Journey Medical 更好</li>
<li>大型股定義及如何投資</li>
<li>博通股票暴跌 20%——但華爾街認為其將飆升至 500 美元</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>忘掉芯片：AI 反彈的 4 個工業投資機會</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>MongoDB 可能會創下新高——但你需要迅速行動</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding DERM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Journey Medical Corporation (NASDAQ:DERM - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有 DERM 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 Journey Medical Corporation（納斯達克代碼：DERM - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=DERM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Journey Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Journey Medical 嗎？</h2>
</div><p>Before you consider Journey Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Journey Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就購買，以便在更廣泛的市場注意到之前……而 Journey Medical 並不在名單上。</p>
</div><p>While Journey Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Journey Medical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Sheets Smith 投資管理公司向 Journey Medical Corporation $DERM 投資了 946,000 美元